Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments. In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed. These MAbs have shown promising preclinical activity and`chimeric' and`humanized' MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy. In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer. Oncogene (2000) 19, 6550 ± 6565.
Introduction
Human tumors express high levels of growth factors and their receptors, and many types of malignant cells appear to exhibit autocrine or paracrine-stimulated growth. Among the best studied growth factor receptor systems has been the EGF receptor family (also known as type I receptor tyrosine kinases or ErbB tyrosine kinase receptors). This family is comprised of four homologous receptors: the epidermal growth factor receptor (ErbB1/EGFr/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4) (reviewed in Klapper et al., 2000; Olayioye et al., 2000) . These receptors are composed of an extracellular binding domain, a transmembrane lipophilic segment, and an intracellular protein tyrosine kinase domain with a regulatory carboxyl terminal segment. ErbB3, however, is dierent from the other members in that it has a de®cient tyrosine kinase domain.
The ErbB receptors become activated by dimerization between two identical receptors (homodimerization) or between dierent receptors of the same family (heterodimerization) (Lemmon and Schlessinger, 1994) . The mechanisms that promote the formation of receptor dimers include ligand binding and high receptor density due to overexpression (Lemmon and Schlessinger, 1994) . There is a multiplicity of ErbB receptor ligands that drive the formation of homo-or heterodimeric complexes among the four ErbB receptors (Lemmon and Schlessinger, 1994; Klapper et al., 2000; Olayioye et al., 2000) .
At least six dierent ligands, known as EGF-like ligands, bind to the EGFr (ErbB1). These ligands include epidermal growth factor (EGF), transforming growth factor alpha (TGF-a), and amphiregulin, that only bind to the EGFr and heparin binding EGF (HB-EGF), betacellulin, and epiregulin that can bind to both EGFr and ErbB4 (Klapper et al., 2000; Olayioye et al., 2000) . EGF-like ligands induce formation of ErbB1/ErbB1 homodimers and ErbB1/ ErbB2 heterodimers, although ErbB1/ErbB3 and ErbB1/ErbB4 heterodimers can be detected occasionally. A second class of ligands, collectively termed neuregulins (also known as neu dierentiation factors and heregulins) binds directly to ErbB3 and/or ErbB4 (Holmes et al., 1992; Lupu et al., 1992; Tzahar et al., 1994) . Neuregulin-1 and neuregulin-2 bind to either receptor, while neuregulin-3 (Zhang et al., 1997) and neuregulin 4 bind only to ErbB4. Neuregulins induce the formation of ErbB3/ErbB3 or ErbB4/ErbB4 homodimers and ErbB2/ErbB3 or ErbB2/ErbB4 heterodimers (Klapper et al., 1999 (Klapper et al., , 2000 .
In contrast with the other ErbB receptors, a soluble ligand for the ErbB2 receptor has not been identi®ed to date. However, ErbB2 is now known to be the preferred co-receptor for the ErbB1, ErbB3 and ErbB4 (Klapper et al., 1999 (Klapper et al., , 2000 . This preference for heterodimerization within the ErbB receptor family explains how ErbB2 signals in the absence of a cognate ligand. The heterodimers between ErbB2 and the other ErbB receptors have relatively high ligand anity, potent signaling activity and are synergistic for cell transformation (Klapper et al., 1999) . These features may be related to the ability of ErbB2 to decelerate the rate of ligand dissociation (Sliwkowski et al., 1994; Karunagaran et al., 1996) , which could cause a prolonged signaling by all ErbB family ligands. Overall, ErbB2 is proposed as a master coordinator of the signaling network that functions as a shared co-receptor for ErbB ligands, rather than as a receptor that mediates the action of a speci®c (unidenti®ed) ligand (Klapper et al., 1999 (Klapper et al., , 2000 Olayioye et al., 2000) . However, within the erbB receptor family, the combinatorial possibilities are numerous, and each homo-and heterodimer receptor complex may activate dierent signaling pathways that elicit speci®c cellular responses, resulting in an enormous signaling diversity.
Following receptor dimerization, activation of the intrinsic protein tyrosine kinase activity and tyrosine autophosphorylation occur. These events lead to the recruitment and phosphorylation of several intracellular substrates, leading to mitogenic signaling and other cellular activities (Pawson and Schlessinger, 1994; Alroy and Yarden, 1997; Riese and Stern, 1998) . There is a requirement for receptor tyrosine kinase activity in receptor-mediated cellular signaling, since receptors lacking kinase function as a result of mutations of the ATP binding site do not display a full range of biochemical responses following ligand binding (Chen et al., 1987; Pawson and Schlessinger, 1994 ). Apparently, a major signaling route of the ErbB family is the Ras-Raf-MAP-kinase pathway which has been under investigation for over a decade (Alroy and Yarden, 1997) . Another important pathway in erbB receptor signaling is the one constituted by PI-3-kinase and the downstream protein kinase Akt (Burgering and Coer, 1995; Muthuswamy et al., 1999) . After its activation, Akt transduces signals that regulate multiple biological processes including apoptosis, gene expression, and cellular proliferation (reviewed in Chan et al., 1999) . Akt is likely to send survival (anti-apoptotic) signals by phosphorylating multiple targets, including the BCL-2 family member BAD (Datta et al., 1997) and the cell death pathway enzyme caspase-9 (Cardone et al., 1998) . Akt has also a prominent role in the regulation of cell cycle progression (Chan et al., 1999) . In lymphoid cells, Akt transduces PI-3-kinase-dependent IL-2 signals that phosphorylate Rb and promote the activation of E2F (Brennan et al., 1997) . The phosphorylation of Rb by Akt transduced signals could be the result of a combination of mechanisms, including downregulation of the cyclin-dependent kinase inhibitor p27 KIP and enhanced expression of G1 cyclins (Chan et al., 1999 and references therein) . There is growing evidence that anti-erbB receptor strategies may at least partially exert their antitumor activities by interfering with the MAPK and Akt pathways.
Many of the physiologic activities of the ErbB signaling network in regulating normal cell growth and dierentiation are felt to involve mesenchymeepithelial crosstalk and interactions between neurons and muscle, glia and Schwan cells (Burden and Yarden, 1997; Klapper et al., 2000; Olayioye et al., 2000) . In these situations the cellular source of ligand may be dierent from the cell that undergoes receptor activation. Expression of both ErbB receptors and their ligands is detected in human cancer cells (reviewed in Salomon et al., 1995) . Several lines of evidence suggest that the EGFr and ErbB2 play a role in many human cancers and, therefore, are candidate targets for cancer therapy: these receptors are frequently overexpressed in human tumors ± EGFr in many types of cancer, and ErbB2 in the case of breast, ovarian and stomach cancers (Salomon et al., 1995) ; their overexpression typically confers a more aggressive clinical behavior; and monoclonal antibodies and direct tyrosine kinase inhibitors directed at these receptors inhibit tumor growth in human xenograft models. Although an alternative approach would be to target the growth factors, the targeting of the receptors is preferred due to the multiplicity of ligands for a given receptor and the lack of known ligands for ErbB2, and the possibility of yet other unknown ligands to be identi®ed. Two of these monoclonal antibodies, trastuzumab (Herceptin 1 ) against ErbB2 and C225 against EGFr, have shown activity in advanced clinical trials, and trastuzumab was approved in 1998 for the treatment of patients with ErbB2-overexpressing metastatic breast cancer. In addition, new strategies involving speci®c inhibitors of the tyrosine kinase portions of these receptors have also shown promising activity in early clinical trials.
Targeting the EGF receptor
The early 1980s, when we began to consider ways to inhibit EGF receptor activity, was an exciting time in the receptor ®eld. Dr Stanley Cohen had accomplished both the identi®cation of EGF (Cohen, 1962) and the puri®cation of its receptor (Cohen et al., 1980) . This provided molecular characterization of the two components of an`autocrine' growth-promoting mechanism which explained the unregulated proliferation of some cancer cells, as was described in a landmark publication by Drs Michael Sporn and George Todaro (Sporn and Todaro, 1980) . Dr Gordon Sato synthesized research going back many decades, by showing that the need for growth factors accounted for the requirement for serum in cell culture (Barnes and Sato, 1980) . And the equivalent tyrosine kinase functions of the EGFr and the src oncogene were described (Cooper and Hunter, 1981; Chinkers and Cohen, 1981; Erickson et al., 1981) . It turned out that the EGF receptor was a cellular oncogene, with direct homology to the v-erbB oncogene (Xu et al., 1984; Lin et al., 1984; Ullrich et al., 1984) .
These studies, and the observation that EGFr are markedly overexpressed on a large variety of epithelial cancers (reviewed in Salomon et al., 1995) , led us to hypothesize that if we could block the binding of EGF to its receptor, we might prevent receptor activation and thereby inhibit cell proliferation. Cancer cells were known at the time to be`dysregulated' in their growth and could inappropriately bypass the restriction point in G 1 phase (now known as the G 1 checkpoint), in situations where deprivation from essential amino acids, energy sources or certain growth factors caused normal cells in culture to avoid death by undergoing growth arrest (reviewed in Pardee, 1989) . Therefore, we hypothesized that cancer cells might be selectively sensitive to deprivation from the EGF-mediated growth signal, compared with non-malignant cells. The rationale for anti-receptor therapy has been reviewed Mendelsohn, 1997 Mendelsohn, , 2000 .
Anti-EGFr monoclonal antibodies that block receptor kinase
Production and characterization of Anti-EGF receptor monoclonal antibodies A series of anti-EGF receptor MAbs were produced with inhibitory activity against cells bearing EGF receptors Sato et al., 1983; Rodeck et al., 1987; Aboud-Pirak et al., 1988) . In collaboration with Dr Sato, our laboratory produced two murine MAbs, 225 IgG1 and 528 IgG2a, which bind to the receptor with anity comparable to the natural ligand (K d =1.5 ± 2 nM), compete with ligand binding, and block activation of receptor tyrosine kinase by EGF or TGF-a Sato et al., 1983; Gill et al., 1984) . In addition, MAb 225 induces antibody-mediated receptor dimerization (without activation of the tyrosine kinase) resulting in receptor down-regulation, and this eect appears to be important for its growth inhibitory capacity (Fan et al., 1994) . As a result of the blockade of activation of receptor tyrosine kinase, these antibodies prevent EGF-and TGF-a-induced stimulation of growth rate in a variety of human cells that express both EGF receptors and ligand Sato et al., 1983; Mendelsohn and Baselga, 1995; Mendelsohn, 1997 Mendelsohn, , 2000 .
The inhibitory eects of these MAbs in cell culture experiments were con®rmed in vivo against human tumor xenografts of A431 vulvar squamous carcinoma cells and MDA 468 breast adenocarcinoma cells, both of which express extremely high levels of EGF receptors . Based on the promising antitumor activity, both in culture and in vivo, MAb 225 was selected for clinical development. A chimeric human:murine version of MAb 225 (IMC-C225) was produced to obviate the immune response produced in humans by repetitive exposure to murine MAb 225 (Goldstein et al., 1995) . The chimeric antibody IMC-C225 binds to the EGF receptor with higher anity (K d =0.39 nM) than the murine MAb and the natural ligands, and is capable of inducing complete regressions of well established human tumor xenografts overexpressing the EGF receptor.
Recently, a fully humanized anti-EGFr MAb, ABX-EGF was produced (Yang et al., 1999) . MAb ABX-EGF binds to the EGFr with high anity (K d =0.5 nM), prevents ligand binding and eradicates well established A431 cell xenografts in nude mice.
The enhanced activity of these antibodies against xenografted human cancer cells, resulting in complete eradication of well established tumors compared to the mainly cytostatic activity in cell culture, suggested that alternative mechanisms may be contributing to their anti-tumor eects in vivo.
Mechanisms of action of anti-EGFr monoclonal antibodies Anti-EGFr MAbs have a number of molecular and biological eects upon cells bearing EGFr, each of which may be contributing to anti-tumor activity. Seven possible mechanisms of action are listed in Table  1 , and are summarized in this section.
(i) The direct mechanism of action of mAb 225 is inhibition of tyrosine kinase activation. When A431 squamous carcinoma cells are incubated in culture, autocrine TGF-a produced by the cells activates EGFr tyrosine kinase. Addition of mAb 225 to the cultures results in a concentrationdependent inhibition of receptor tyrosine kinase activity. This cannot be accounted for by the observed modest reduction in the amount of EGFr protein resulting from an increase in receptor internalization and catabolism mediated by the antibody Gill et al., 1984; Goldstein et al., 1995) . Thus, MAb C225 is acting as a drug, a tyrosine kinase inhibitor speci®c for the EGFr. (ii) When nontransformed human cells growing in culture were exposed continuously to saturating concentrations of MAb 225, cell cycle traversal was arrested in G 1 phase. This has been shown with human foreskin ®broblasts, a colon adenoma cell line, and MCF10A immortalized mammary cells Markowitz et al., 1990; Chou et al., 1999) . The response of cultured malignant cell lines to MAb 225 varies from slowing of the proliferation rate to complete arrest in G 1 phase of the cell cycle, rarely followed by cell death (Wu et al., 1995; Peng et al., 1996) . Control MAbs 455 and R1 (Water®eld et al., 1982) , both of which bind to the receptor but do not block the binding of EGF or TGF-a and do not inhibit activation of tyrosine kinase, did not inhibit the growth of cultured cells Markowitz et al., 1990; Wu et al., 1995) . In cultures of A431 squamous carcinoma cells, DiFi colon adenocarcinoma cells, and DU145 prostate adenocarcinoma cells treated with MAb 225, inhibition of cyclin-dependent kinase 2 (CDK2) activity was observed. This could be accounted for by a rise in the levels of inhibitor p27
Kip1 bound to CDK (Figure 1 ) (Peng et al., 1996; Wu et al., 1996; Fan et al., 1997) . There was no change in the levels of inhibitor p21
Cip1
. Similar changes were observed in the MCF10A breast cell line, but with an additional decline in cyclin D levels (Chou et al., 1999) .
Growth arrest or tumor regression was observed in well-established human tumor xenografts when mice were treated with MAb C225 (Goldstein et al., 1995) . Histological staining of human bladder cell tumors in treated nude mice con®rmed the cell culture data, showing a decline in proliferating cell nuclear antigen, accompanied by a rise in p27
Kip1 (Perrotte et al., 1999) . (iii) In the case of DiFi colon adenocarcinoma cells, cell cycle arrest at 24 h was followed by programmed cell death at 48 h when cultures were treated with MAb 225 (Wu et al., 1995) . These cells carry undetectable levels of Bcl-2, and in antibody-treated cultures, the levels of Bax rose Inhibits repair or recovery, after chemotherapy or radiation within 8 h and were sustained until apoptosis occurred (Mandal et al., 1998) . Recent published studies showed that C225 induced elevation in the activities of caspase-3, -8 and -9 in concert with the induction of apoptosis in DiFi cells (Liu et al., 2000) . A rise in Bax in head and neck cancer cells treated with C225 has been reported (Huang et al., 1999) . An increase in the phosphorylated (inactive) form of Bcl-2 in ZR75 breast adenocarcinoma cells was observed in one study , and another study reported a decrease in Bcl-2 levels in a head and neck cancer line in response to C225 (Huang et al., 1999) . Finally, MAb 225 was also found to sensitize cells to tumor necrosis factor (Fong et al., 1992) . Thus, a variety of proapoptotic mechanisms are activated when the EGF receptor signaling pathway is blockaded by MAb 225. EGF and TGF-a appear to function in part as survival factors, inhibiting the levels of proapoptotic molecules in addition to stimulating cell proliferation. However, in most cases that were studied, when cells in culture were subjected to inhibition of their EGF receptors, the proapoptotic pathways were not activated to the point of initiating programmed cell death, and most cells exhibited only slower proliferation or G 1 arrest. (iv) A possible explanation for the eectiveness of therapy with mAb C225 in xenograft models is the inhibition of antiangiogenesis (Petit et al., 1997; Perrotte et al., 1999; Bruns et al., 2000a) . Cultured bladder cancer cells were shown to secrete high levels of vascular endothelial growth factor, interleukin 8, and basic ®broblast growth factor into the culture medium, and this production of angiogenesis factors was reduced by the addition of MAb C225. When orthotopic xenografts of these bladder cancer cells were excised and examined histologically, 3 weeks of treatment with C225 produced a marked decrease in the presence of new blood vessels and a marked reduction in the amounts of vascular endothelial growth factor, interleukin 8, and basic ®broblast growth factor present in the tumor cells (Perrotte et al., 1999) . Similar observations were made with xenografted A431 squamous cervical carcinoma cells (Petit et al., 1997) and a pancreatic carcinoma cell line (Bruns et al., 2000a) . Thus, it appears that activity of the EGF receptor signal transduction pathway is required for stimulation of angiogenesis by these malignant cells. (v) When studies with xenografts of bladder carcinoma cells were carried out in the orthotopic model, the cancer cells metastasized to the lymph nodes and lungs. If tumor-bearing animals were treated with mAb C225 beginning 28 days after tumor implantation, metastases were not observed, compared with the presence of lymph node metastases in eight of eight untreated control animals and lung metastasis in three of eight controls. Histological staining showed the presence of high levels of matrix metalloproteinase 9 in the tumor cells of control animals and a marked reduction in matrix metalloproteinase 9 in the treated animals (Perrotte et al., 1999) . These anti-metastatic properties of EGFr blockade may add to its ecacy as an anti-cancer therapy. (vi) While C225 is a chimeric antibody of the human IgG1 class which can mediate immune cytotoxicity, there is clear evidence that immune function is not required for mAb-mediated inhibition of human tumor xenograft growth. A`disarmed' F(ab') 2 fragment of MAb 225 was able to inhibit xenograft growth, although not quite as eectively as the complete MAb. While immune eects are not essential, it is possible that they could be contributing to the activity of anti-EGFr MAb in vivo. (vii) The ®rst report of enhanced antitumor activity when an anti-EGFr MAb was combined with chemotherapy came from the laboratory of Dr Michael Sela (Aboud-Pirak et al., 1988). We were able to demonstrate synergystic antitumor activity against well-established human tumor xenografts of both adenocarcinoma and squamous carcinoma cell lines, when murine MAb 255 or 528 treatment was combined with the maximum tolerated doses of either doxorubicin or cisplatin Fan et al., 1993) . Treatment either with drug alone or with antibody alone merely reduced tumor growth or had little eect, whereas combined therapy eradicated well-established xenografts ( Figure 2) . A third study showed synergystic, curative antitumor activity when MAb 225 or 528 treatment was combined with paclitaxel, this time with suboptimal doses of the chemotherapeutic agent . And another study showed synergystic antitumor activity of mAb C225 when given in combination antibody, subjected to SDS-gel electrophoresis, and immunoblotted with anti-CDK2 or anti-CDK4 antibodies. The amount of p27
Kip1 increased with time of culture in the presence of MAb C225 and was found to be associated with increasing amounts with CDK2. CDK2 activity showed a corresponding decrease (data not shown). Adapted from (Wu et al. (1996) with topotecan against a colon adenocarcinoma xenograft . These data demonstrate that blockade of EGF receptors by MAb 225 or MAb C225 can potentiate the antitumor activities of a variety of chemotherapeutic agents that have dierent mechanisms of action.
The mechanism for this synergism is under study. Preliminary data suggest that repair of drug-induced damage may be hampered by inhibition of the EGFr signaling pathway. We favor the possibility that in the presence of cellular damage from chemotherapy, EGF or TGF-a becomes a survival factor rather than a growth factor, tipping the balance further towards drug-induced apoptosis. This is consistent with the role of growth factors as survival factors in cultures of hematopoietic cells and in cultured epithelial tumor cells driven to proliferate by expression of an oncogene (Meikrantz and Schlegel, 1995; Evan et al., 1992) . Since growth factors generally do not serve as survival factors for epithelial cells, it is likely that normal epithelial cells may be less susceptible than malignant cells to cytotoxicity from the combination of antiEGFr therapy and chemotherapy.
As with chemotherapy, preclinical studies have also shown that anti-EGFr mAbs enhance the antitumor eect of radiation therapy (Huang et al., 1999; Milas et al., 2000) . In A431 human tumor xenografts, response to radiation was enhanced by a factor of 3.6 with concomitant use of IMC-C225. These ®ndings are of great clinical promise since most epithelial tumors that are currently treated with radiation express high levels of EGFr. Examples include carcinomas of the head and neck area, non-small cell lung cancer, esophageal carcinoma, cervix cancer and rectal cancer, among others. Results from a phase I/II clinical trial of IMC-C225 plus radiation in patients with advanced head and neck malignancies suggest that similar eects will be seen in patients.
A newer approach to enhancing the activity of antiEGFr MAbs is their use in combination with inhibitors of related growth factor receptors. In the laboratory, the combinatorial use of anti-EGFr and anti-ErB2 mAbs results in additive anti-proliferative eects, suggesting a potential bene®t of this combined therapy in the treatment of human cancers stimulated by EGFr and ErbB2 signals (Ye et al., 1999) . Other approaches to augmenting the activity of anti-EGFr MAbs is their use in combination with inhibitors that act on downstream signaling molecules, such as farnesyltransferase inhibitors designed to suppress ras activity (SeppLorenzino et al., 1996) , or with inhibition of protein kinase A (Ciardiello et al., 1996) .
Clinical experience with anti-EGF receptor monoclonal antibodies This discussion will focus on IMC-C225, which is the only anti-EGFr MAb that has reached phase II and III-level clinical trials. In an initial phase I study, a single dose of murine MAb 225 was found to be safe and satisfactory localization to tumors was achieved (Divgi et al., 1991) . However, all patients produced human anti-mouse antibodies which could have precluded the subsequent administration of multiple doses of antibody. To obviate the immune response, the chimeric human:murine version of MAb 225 (IMC-C225) was produced (Goldstein et al., 1995) . An initial series of phase I trials with IMC-C225 alone or in combination with cisplatin was conducted in patients with advanced, EGFr-overexpressing tumors (Baselga et al., 2000a) . A primary goal in these trials was to de®ne the optimal dose and schedule at which complete and sustained receptor saturation was achieved. Analysis of data from three . MAb 225 (1 mg) was given intraperitoneally on day 1 and twice a week thereafter for a total of 10 doses. Treatment with either doxorubicin alone or MAb alone resulted in transient inhibition of growth. Doxorubicin in combination with MAb 225 had a pronounced antitumor activity. Arrows show days on which treatment was administered . (b) Antitumor activity of MAb 225 in combination with cisplatin (CDDP) on well established A431 squamous cell carcinoma xenografts. Treatment was started on day 8. Cisplatin (150 mg/25 g body weight) was given intraperitoneally on day 8 and 18. MAb 225 (1 mg) was given intraperitoneally on day 8 and twice a week thereafter for a total of 8 doses. Cisplatin in combination with MAb 225 had a pronounced antitumor activity with no recurrence of tumors after 6 months of follow up. Arrows show days on which treatment was administered (Fan et al., 1993) The EGF receptor family as targets for cancer therapy J Mendelsohn and J Baselga of the phase I trials has shown IMC-C225 pharmacokinetics to be non-linear, with saturation of drugelimination pathways occurring at doses between 200 and 400 mg/m 2 . The initial de®nition of the optimal dose was based on preclinical studies with MAb 225 and IMC-C225. In cell culture, addition of MAbs 225 or IMC-C225 at levels at least 20 times the receptor binding anity resulted in receptor saturation and maximal inhibition of growth Kawamoto et al., 1984; Goldstein et al., 1995) . In nude mouse models, saturating levels of MAb 225 in the blood produced optimal antitumor activity against the xenografts . These observations served to de®ne initially the optimal biologic dose of IMC-C225 as the lowest dose that would continuously maintain serum concentrations of the antibody above 30 nM. While this criterion was met in trials with the 100 mg/m 2 weekly dose, the systemic clearance of IMC-C225 was not yet saturated at this dose level (Figure 3 ). Further escalation of the dose of IMC-C225 was conducted until complete saturation of antibody clearance was observed at weekly doses of between 200 and 400 mg/m 2 . At these doses, the mean circulating IMC-C225 levels were sustained above 200 nM (Figure 3 ), which is way above the optimal concentration of antibody that inhibits EGFr-dependent tumor cells ex vivo. These data strongly suggested that the concentration of the antibody required for EGFr saturation in preclinical models might not directly correlate with what is required in humans. Indeed, EGFr are widely expressed in normal tissues (e.g. skin and liver), providing additional competing antibody-binding sites. The dose and schedule required for saturation of these receptors could not have been predicted from studies with human xenografts in nude mice, due to the lack of MAb 225 or IMC-C225 binding to the murine receptor. As a result, the optimal dose was rede®ned as the dose schedule that completely saturates IMC-C225 systemic clearance. In addition, many patients treated with the higher doses of IMC-C225 experienced a skin rash that is felt to be a biological eect related to inhibition of the EGFr since this receptor has a critical role in skin growth. This observation further suggests that the EGFr can be successfully targeted and functionally modulated in vivo by IMC-C225.
The need to ®nd an optimal biological dose for patients treated with these antibodies emphasizes the relevance of developing reliable biological markers in trials that evaluate agents acting on the EGFr. Although these early phase I trials with IMC-C225 did not include the analysis of biological markers, other trials with anti-EGFr antibodies and follow up studies with C225 and other anti-EGFr MAbs have shown that antibody binding to tumor EGFr and saturation of the receptors can be achieved (Modjtahedi et al., 1996; Perez-Soler et al., 1994 . The pharmacokinetic ®ndings with C225 are in agreement with a prior phase I single dose clinical trial with a dierent murine anti-EGFr MAb, RG 83852, in patients with non-small cell lung cancer or head and neck tumors (Perez-Soler et al., 1994) . In that study, EGFr status in biopsied tumor samples assessed by immunohistochemistry and assays of EGFr tyrosine kinase activity showed receptor saturation of 550% at doses 5200 mg/m 2 (Perez-Soler et al., 1994) . In vivo receptor saturation in patients treated with IMC-C225 has been documented (Perez-Soler et al., 1998) . Overall, the results from these studies support the hypothesis that saturation of antibody binding to the EGFr in humans will occur only when complete saturation of drug clearance (i.e. zero order kinetics) is achieved.
In another Phase I trial, the rat anti-EGFr MAb ICR62 was evaluated in 20 patients with head and neck or lung cancer (Modjtahedi et al., 1996) . This antibody eectively blocks the binding of EGF, TGF-a and HB-EGF to the EGFr, inhibits the growth of cultured human tumor cell lines which overexpress the EGFr, and eradicates such tumors when grown as xenografts in nude mice. In that trial, no serious toxicity was observed and four patients developed human anti-rat antibodies. Biopsies obtained from metastatic lesions showed localization of MAb ICR62 to the membranes of tumor cells, more prominently at higher doses (Modjtahedi et al., 1996) . The fully human anti-EGF receptor mAb, ABX-EGF, has now entered phase I clinical trials (Yang et al., 2000) . A series of phase I/II studies of IMC-C225 given alone or in combination either with chemotherapy or radiation have now been completed. Bonner et al. (2000) recently reported an update of clinical results with IMC-C225 when given in combination with radiation therapy in patients with head and neck tumors. In the study, escalating doses of IMC-C225 were added to conventional radiation therapy in patients with unresectable head and neck carcinomas. Among 15 evaluable patients there was a 100% response rate, and 13 out of 15 patients achieved a complete remission. Further, the median duration of response has not been reached at a follow up time of 17 months. These results were considered to be highly encouraging, taking into consideration that the expected response rate in this patient population with radiation alone would have been in the 60% range. The results of this phase I/II study, have led to the initiation of a phase III randomized study of radiation +IMC-C225.
Similarly con®rming preclinical data, a phase I/II study has reported six complete plus partial responses in nine evaluable patients with advanced head and neck carcinomas and reversal of cisplatin resistance in three of these patients, when cisplatin was given in combination with IMC-C225 . In two of the three remaining patients there was stabilization of disease. This initial series has now been expanded and con®rmed (Rubin et al., 2000) . A follow-up phase II study of cisplatin plus IMC-C225 in patients with cisplatin refractory head and neck tumors and a randomized phase III trial of cisplatin with or without IMC-225 are currently ongoing to further document this interaction. The addition of IMC-C225 to CTP-11 in patients with metastatic colon carcinoma that previously failed CTP-11 resulted in several responses to therapy and, hence, reversal of CPT-11 resistance (Rubin et al., 2000) . This observation is now being followed up with a con®rmatory phase II study of C225 plus CTP-11 in patients with advanced, CTP-11 refractory colorectal carcinoma.
Across nine clinical trials involving over 500 patients, IMC-C225 has been shown to possess low immunogenicity: Human Antibodies against Chimeric Antibodies (HACAs) have been detected in only 4% of the patients (Khazaeli et al., 2000) ; notably, none of these patients with HACA experienced allergic or anaphylactic reactions, and the HACA responses had no clinically limiting eect following repeated weekly infusions of MAb. The most clinically relevant adverse events were allergic reactions and skin toxicities. Seven per cent of patients have experienced IMC-C225-related allergic reactions, all of which occurred during the ®rst infusion, and 4% experienced grade 3/4 reactions. All patients responded to standard treatment and recovered without sequelae (Cohen et al., 2000) .
Skin reactions, which are now considered to be expected events associated with IMC-C225 treatment, tend to moderate with repeated administration and resolve without sequelae after cessation of treatment. In summary, co-administration of IMC-C225 with chemotherapy or radiation has been well tolerated.
Inhibitors of EGF receptor tyrosine kinase acting intracellularly
The tyrosine kinase activity of the EGFr is required for the biochemical responses induced by this receptor (Pawson and Schlessinger, 1994; Chen et al., 1987) . Over the last decade drug discovery eorts have produced a variety of chemical structures that inhibit the EGFr tyrosine kinase (Levitzki and Gazit, 1995; Table 2 ). These EGFr tyrosine kinase inhibitors dier among themselves in their potency, degree of speci®city against the EGFr, reversibility of action, and bioavailability ± with orally bioavailable compounds usually being preferred for clinical development.
Quinazoline compounds represent a class of competitive inhibitors of the ATP binding site that can be highly selective for the EGF receptor tyrosine kinase (Fry et al., 1994; Klohs et al., 1997) . One of the initial compounds, PD153035, has been extensively used as a lead to creating new and more clinically suitable drugs of this family (Fry et al., 1994) . PD153035 reversibly inhibits the EGFr tyrosine kinase at picomolar concentrations and inhibits EGFr autophosphorylation at nanomolar concentrations (Fry et al., 1994) . PD153035 also blocks EGF-mediated mitogenesis and oncogenic transformation in ®broblasts overexpressing EGFr. We further studied the capacity of PD153035 to inhibit ligand-induced EGFr phosphorylation and cell growth in a panel of human carcinoma cell lines with various levels of EGFr and/or ErbB2 overexpression (Bos et al., 1997) . In our studies, PD153035 suppressed proliferation and clonogenicity with greater ecacy in cell lines expressing greater numbers of receptors and did not signi®cantly aect proliferation of cells expressing high levels of ErbB2 and normal levels of EGF receptor. PD153035 was cytostatic, and cells regained their growth capacity and ligand-sensitivity upon drug removal. These ®ndings suggest that continuous drug exposure would be required to achieve clinical ecacy and in the design of ongoing clinical studies this need for prolonged drug exposure has been taken into account.
Preclinical studies with several quinazolines, CP-358,774 (Moyer et al., 1997) , AG-1478 (Busse et al., 2000) and ZD1839 (Budillon et al., 2000) have shown that treatment of EGFr expressing cancer cells with these agents results in blockade of cell cycle progression at the G 1 phase. This G 1 arrest is preceded by accumulation of p27 KIP1 and a marked accumulation of hypophosphorylated Rb protein (Moyer et al., 1997; Budillon et al., 2000; Busse et al., 2000) . The role of p27 KIP1 in quinazoline-mediated G 1 arrest appears critical since p27 KIP1 antisense oligonucleotides resulting in a decrease of p27 protein levels markedly attenuated the quinazoline-induced G 1 arrest (Busse et al., 2000) . The G 1 arrest and p27 KIP1 upregulation have been shown to be due to interruption of the PI-3-kinase pathway and not of the MAPK pathway (Busse et al., 2000) . In general, these results con®rm and extend the previous observations on the results of EGFr blockade with MAb.
A new class of quinazolone derivates, the acrylamido-4-aminiloquinilines, that speci®cally inactivate both the EGFr and ErbB2 in an irreversible manner, has been produced. Irreversibility can be achieved through selective covalent binding to an individual cysteine located within the ATP binding site of the EGFr, and is consistent with its activity against ErbB2, which has an analogue cysteine residue in its ATP binding pocket (Fry et al., 1998) . PD168393 is a prototype of these compounds, and comparison with an equally potent but reversible analogue showed that the irreversible inhibitor has stronger in vivo antitumor activity against A431 xenografts (Fry et al., 1998) . CI-1033, a compound that similarly inhibits both the EGFr and erbB2 in an irreversible fashion, has demonstrated potent antitumor activity in xenografts models expressing both the EGFr and erbB2, and is currently being evaluated in phase I studies (Smaill et al., 1999) . These agents, which inhibit two receptors of the same family of receptors, are known as`pan-HER' inhibitors.
Two quinazolones, ZD1839 and CP-358,774, have been evaluated in phase I and II trials. So far, studies with ZD1839 have progressed rapidly in the clinic and a more detailed description of its preclinical and clinical activity is provided.
Laboratory studies with ZD1839 ZD1839 is a lowmolecular weight, synthetic anilinoquinazoline. In vitro, ZD1839 potently inhibited tyrosine kinase activity of EGFr isolated from human vulvar squamous carcinoma cells, with an IC 50 of 0.023 to 0.079 mM . In contrast, ZD1839 showed minimal activity against other tyrosine kinases such as erbB2, KDR, c-¯t, or against serine/threonine kinases including protein kinase C, MEK-1, and ERK-2, with IC 50 values at least 100-fold higher than that for EGFR. ZD1839 prevented autophosphorylation of EGFr in a number of tumor cell lines in culture (IC 100 0.16 ± 0.8 mM) (Woodburn et al., 1997) . A further study investigated the eect of ZD1839 on mRNA for the nuclear transcription factor, c-fos, which has been proposed as a downstream biomarker for EGFr tyrosine kinase activation . In addition, in fashion similar to MAb IMC-C225 (Peng et al., 1996; Fan et al., 1997) and other tyrosine kinase inhibitors (Moyer et al., 1997; Busse et al., 2000) , ZD1839 has been shown to cause a delay in cell cycle progression in human head and neck squamous cell carcinoma cell lines that is associated with a dose-and time-dependent upregulation of the CDK inhibitor, p27 Kip1 . Expression of p27 Kip1 reached a peak after 24 h, coinciding with a dose-dependent downregulation of CDK2 activity (Budillon et al., 2000) . This suggests that p27
Kip1 plays a key role in ZD1839-induced cell cycle perturbation by decreasing CDK2 activity, leading to G 1 growth arrest.
Further support for the development of ZD1839 as an anticancer agent was provided by studies with tumor cell lines in culture and human tumor xenografts in nude mice. ZD1839 inhibited EGF-stimulated growth of KB oral carcinoma cells and growth of ovarian, colon and breast cancer cells in soft agar . Daily oral administration of single-agent ZD1839 to athymic mice caused marked reductions in tumor growth in a variety of human tumor xenografts. In one study, ZD1839 (200 mg/kg/day) induced tumor regression in A431 xenografts for up to 4 months; this was reversible on withdrawal of treatment . ZD1839 also demonstrated antitumor activity in nude mice bearing human GEO colon cancer xenografts . The antiproliferative activity of ZD1839 in combination with a number of cytotoxic drugs (cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, doxorubicin, etoposide, topotecan and raltitrexed) has been assessed against a variety of human cancer cell lines Sirotnak et al., 2000; Woodburn et al., 2000) . Coadministration of ZD1839 was found to enhance the growth-inhibitory eects of all cytotoxic drugs tested. These results provide evidence con®rming the earlier studies with MAbs, which showed that interfering with (Smaill et al., 1999) 7 intact cells 9 intact cells PD153035 29 2300 NO Preclinical (Fry et al., 1994) PD 168393 0.70 Not reported YES Preclinical studies (Fry et al., 1998) 4 EGFr signaling is a valid approach to improve the ecacy of chemotherapy.
Anti-EGFr strategies may also play a role in tumor prevention. The EGFr is important in mammary gland ductal development (reviewed by Olayioye et al., 2000) . Interestingly, ZD1839 treatment has been found to result in a decrease in proliferation and increased apoptosis of xenografts of surgically removed ductal carcinoma in situ (DCIS) breast tissue implanted into nude mice, while anti-erbB2 MAbs had no eect (Chan et al., 2000) .
Clinical experience with ZD1839 Studies in humans have shown that following administration of single and repeated oral doses of ZD1839, peak plasma concentrations were reached after 3 ± 7 h and subsequently declined biphasically, with a terminal half-life of between 27 and 49 h (Kelly et al., 1998) . Exposure to ZD1839 (C max and AUC 0-24 ) increased approximately linearly with dose over the dose range 10 ± 700 mg, and there was no apparent change in terminal half-life as the dose increased, or on repeated dosing. Steady state was achieved by day 7 with repeated daily administration, and there was a 2 ± 7-fold increase in exposure (AUC 0-24 ) on day 14 relative to day 1. These data showed that ZD1839 is suitable for once-daily oral administration and that potentially biologically relevant concentrations (i.e., concentrations higher than the IC 90 for in vitro EGFr-tyrosine kinase inhibition) of drug are achievable.
Both intermittent and continuous dosing schedules of oral ZD 1839 have been well tolerated. The most common adverse events were skin rash and diarrhea, which was the dose limiting toxicity at 700 mg/day in one of the reports. The preliminary results suggest that ZD 1839 has promising antitumor activity, particularly against non-small cell lung cancer (NSCLC). In an intermittent dose study of 16 patients with NSCLC, two had partial responses (Ferry et al., 2000) , and four others had some regression or stabilization of disease. Responses have also been seen in the continuous administration and Japanese studies (Baselga et al., 2000a; Nakagawa et al., 2000) .
A phase III randomized clinical trial in NSCLC is evaluating the ecacy of added ZD 1839, given in combination with standard chemotherapy regimens of either gemcitabine/cisplatin or paclitaxel/carboplatin.
An unresolved issue with this new class of compounds is how to identify the optimal dose, i.e. the dose resulting in complete inhibition of the receptor tyrosine kinase, rather than the maximally tolerated dose (MTD) that has been conventionally used with standard cytotoxic agents. In support for a lack of concordance between optimal dose and MTD is the observation that clinical bene®t and responses were not restricted to the highest dose levels. A possibly useful strategy to de®ne the optimal dose would be the use of pharmacodynamic endpoints in skin and tumor biopsies before and during exposure to the drug. Preliminary analysis of skin biopsies from patients participating in the phase I trials have shown that ZD1839 results in substantial changes in EGFr dependent molecules such as phospho-MAPK, p27 KIP1 , phospho-STAT3 and others (Baselga et al., 2000b) . It would be important to determine whether a dose-eect can be observed and to identify the smallest dose resulting in complete receptor inhibition.
Challenges in the clinical development of anti-EGFr agents for the treatment of patients with cancer
IMC-225 has strong activity in the clinic and has not exhibited dose-limiting toxicities. There also have been clinical responses to ZD1839, with diarrhea being the dose-limiting toxicity. While these results are highly encouraging, challenges remain that will only be solved by carefully conducted clinical trials.
First, it remains unclear whether EGFr has to be overexpressed in order to obtain clinical bene®t from anti-EGFr compounds. Although it may be tempting to establish a paralelism between the ecacy of trastuzumab, where there is a requirement for HER2 overexpression for activity in breast cancer, and the ecacy of IMC-C225 or ZD1839, the biology of the EGFr is dierent from that of erbB2. In clinical trials, it will be important to determine the levels of EGFr expression in the tumor, as well as the levels of expression of selected ligands such as TGF-a that are felt to be required for the maintenance of an active EGFr autocrine loop. Then we will be able to determine whether the response to therapy correlates with either expression of high EGFr levels or production of TGF-a (or both).
Second, the most active combinations with conventional chemotherapeutic agents against speci®c cancer will have to be de®ned in well controlled clinical trials. Preclinical data show that addition of IMC-C225 or ZD1839 results in a marked enhancement of the antitumor activity of a wide variety of chemotherapy agents against many human cancer cell types. Therefore, a practical approach has been to design tumorspeci®c phase II or randomized phase III studies, combining the most active known chemotherapeutic agents against a speci®c tumor type with an anti-EGFr agent. In the case of IMC-C225, an alternative and novel approach is testing the response to EGFr blockade plus a chemotherapeutic agent, immediately after patients have failed on that particular chemotherapeutic agent.
ErbB2 receptor as a therapeutic target

ErbB2 in human cancer
ErbB2 has been shown to be overexpressed, most commonly by gene ampli®cation, in a number of human malignancies, including breast, ovarian, and gastric, and more recently, colon, and non-small cell lung carcinoma (reviewed in Salomon et al., 1995) . The most comprehensive studies have been conducted in breast cancer, showing that erbB2 is overexpressed in 25 ± 30% of human breast cancers and that this is predictive of a worse prognosis in patients with primary disease (Slamon et al., 1987 (Slamon et al., , 1989 . In addition, several other lines of experimental evidence support a role for erbB2 in the pathogenesis and clinical aggressiveness of erbB2-overexpressing tumors: the introduction of erbB2 into non-neoplastic cells causes their malignant transformation (DiFiore et al., 1987; Hudziak et al., 1987) , transgenic mice expressing
The EGF receptor family as targets for cancer therapy J Mendelsohn and J Baselga erbB2 develop mammary tumors (Guy et al., 1992) , and MAbs directed at erbB2 inhibit the growth of tumors and of transformed cells that express high levels of this receptor (Drebin et al., 1985 (Drebin et al., , 1986 Lewis et al., 1993; Hynes and Stern, 1994) . A distinct feature of the erbB2 receptor when compared to the EGFr is that the extracellular portion of the receptor can be cleaved and released into the media (Codony-Servat et al., 1999) . This is a regulated process of yet unknown importance, although high levels of extracellular erbB2 in the serum of patients with advanced breast cancer have been associated with a more aggressive clinical behavior and with decreased sensitivity to endocrine therapy and chemotherapy (Leitzel et al., 1995; Harris et al., 2000; Colomer et al., 2000; Lipton et al., 2000) .
Preclinical studies with anti-erbB2 monoclonal antibodies
Laboratory studies with anti-erbB2 monoclonal antibodies as a single agent Several MAbs directed at the erbB2 ectodomain have been developed that speci®cally inhibit the growth of tumor cell lines overexpressing erbB2 (Drebin et al., 1985 (Drebin et al., , 1986 Hudziak et al., 1989; McKenzie et al., 1989; Fendly et al., 1990; Hancock et al., 1991; Stancovski et al., 1991; Kasprzyk et al., 1992) . Genentech produced a series of murine MAbs against ErbB2 that inhibit the proliferation of cultured breast and ovarian tumor cells overexpressing ErbB2 (Hudziak et al., 1989; Fendly et al., 1990; Lewis et al., 1993) . In their extensive studies, a clear relationship between the level of ErbB2 expression and sensitivity to the growth inhibitory eects of the antibodies was observed. One of the most potent growth inhibitory anti-ErbB2 MAbs, 4D5, was`humanized' for further clinical development (Carter et al., 1992) . The resulting recombinant humanized anti-ErbB2 MAb, trastuzumab (Herceptin 1 ), has a higher binding anity for ErbB2 (K d =0.1 nM) than the murine 4D5, has a cytostatic growth inhibitory eect against breast cancer cells overexpressing ErbB2, and is much more ecient in supporting antibody-dependent cellular cytotoxicity against human tumor cell lines in the presence of human peripheral mononuclear cells (Carter et al., 1992; Baly et al., 1997; Pegram et al., 1997a) .
In the ®rst report using trastuzumab against human tumor xenografts, a single dose of antibody inhibited tumor growth by 50% (Tokuda et al., 1996) . Subsequently, we con®rmed the in vivo antitumor activity of trastuzumab against human breast cancer BT-474 xenografts, that overexpress ErbB2 . Repeated administrations of the antibody given at doses equal to or greater than 1 mg/kg resulted in strong growth suppression and eradication of tumors in a signi®cant proportion of animals. This suggested that in our animal model, doses of 1 mg/kg given twice a week result in maximal inhibition of growth (Figure 4 ). This dose level is similar to the one being administered in the clinical trials in patients with advanced breast cancer (2 mg/kg 6 week).
In contrast with anti-EGF receptor MAbs, which act mainly by preventing ligand binding, the mechanism of the inhibitory action of antibodies directed against ErbB2 is not well understood . In fact, mAb 4D5 actually stimulates tyrosine phosphorylation of ErbB2 (Kumar et al., 1991) . However, there are several mechanisms by which anti-ErbB2 MAbs may exert their tumor inhibitory eects. An important feature of both murine 4D5 and trastuzumab is the induction of a marked downregulation of ErbB2 (Hudziak et al., 1989; Kumar et al., 1991; Sarup et al., 1991) . Antibody-induced downregulation of ErbB2 has been shown to induce reversion of the transformed phenotype in ErbB2-transformed cells (Drebin et al., 1985) . A relationship between receptor degradation and antitumor eects of anti-ErbB2 MAbs is supported by a recent study using a large battery of anti-ErbB2 antibodies (Klapper et al., 1997) . In that study, stimulation of ErbB2 receptor phosphorylation was found to be uncoupled from the growth inhibitory eects of the antibodies (Klapper et al., 1997) . Since ErbB2 is the preferred co-receptor for EGFr, ErbB3 and ErbB4, targeting ErbB2 with MAbs or speci®c tyrosine kinase inhibitors is also likely to impair signaling through the other three ErbB receptors of the family. In this regard, trastuzumab has a partial ability to disrupt the formation of ErbB2/ErbB3 and ErbB2/ErbB4 heterodimers, but a relationship between this eect and growth inhibition is not yet established (Reese et al., 1996; Klapper et al., 1997) . Similar to the activity of anti-EGFr MAb IMC-C225, trastuzumab was recently shown to inhibit cell cycle progression by inducing p27
Kip1 and the formation of p27 Kip1 /Cdk2 complexes Lane et al., 2000) . Although the mechanism for this increase in p27 Kip1 has not been described, a possibility is that this process could be Akt-mediated. In this regard, in cultured BT-474 cells, treatment with trastuzumab results in a decrease in their high basal Akt enzymatic activity .
Trastuzumab also induces antibody-dependent cellmediated cytotoxicity against ErbB2-expressing tumor cells in animal models. This process is regulated by both activating and inhibitory receptors for antibody Figure 4 Activity of trastuzumab against well established BT-474 tumor xenografts in athymic mice in two separate experiments. Trastuzumab (HER2) was given intraperitoneally twice a week for 4 weeks at doses of 1, 10 and 30 mg/kg. The control group was treated with a nonspeci®c rhuMAb IgG at a dose of 30 mg/kg. Trastuzumab at doses equal to or greater than 1 mg/kg markedly suppressed the growth of BT-474 xenografts molecules on eector cells (Clynes et al., 2000) . Additional mechanisms that have been proposed include suppression by trastuzumab of angiogenesis (Petit et al., 1997) and metastasis . Recently, trastuzumab has been shown to be a potent inhibitor of basal and induced cleavage of ErbB2 in the cell surface membrane, and to prevent the generation of membrane-bound phosphorylated truncated receptor (p95) (Codony-Servat et al., 2000) .
Laboratory studies of chemotherapeutic agents in combination with anti-erbB2 monoclonal antibodies As in the case of anti-EGFr MAbs, a way to optimize the ecacy of anti-ErbB2 MAbs is to administer them in combination with chemotherapy. The earliest report of this activity with an anti-ErbB2 MAb (Hancock et al., 1991) has been followed by many laboratory studies showing that anti-ErbB2 MAbs can markedly enhance or promote sensitivity to the antitumor eects of the chemotherapeutic agent cisplatin and other drugs (Arteaga et al., 1993 (Arteaga et al., , 1994 Pietras et al., 1994 Pietras et al., , 1998 Pegram et al., 1997b Pegram et al., , 1999 .
Since paclitaxel and doxorubicin are two of the most active chemotherapeutic agents for the treatment of breast cancer, we hypothesized that ®nding enhanced antitumor activity of these drugs when combined with anti-ErbB2 MAbs would have distinct clinical implications . In the BT-474 tumor xenograft mouse model, doses of trastuzumab that modestly inhibited growth of well established tumors eectively enhanced the tumoricidal eects of paclitaxel, and resulted in a striking rate of tumor eradication ( Figure 5 ). Trastuzumab enhanced the antitumor eects of doxorubicin as well, although to a lesser degree than was observed with paclitaxel ( Figure 5 ) . Another report found enhanced antitumor activity by the combination of trastuzumab and doxorubicin, although less than observed with cisplatin (Pietras et al., 1998) . As a possible mechanism of action for the interaction of paclitaxel and trastuzumab, it has been shown that overexpression of ErbB2 activates the cyclin dependent kinase inhibitor p21
Cip1
, which inhibits p34 cdc2 kinase (Yu et al., 1998) . p34 cdc2 kinase activation is required for paclitaxel induced apoptosis and overexpression of ErbB2 blocks paclitaxel-induced apoptosis by inhibiting p34 cdc2 activation (Yu et al., 1998) . This ®nding provides a mechanistic link between ErbB2 overexpression and paclitaxel resistance. It is possible that trastuzumab, by downregulating ErbB2, may prevent or inhibit p21
Cip1 activation and hence restore sensitivity to paclitaxel-induced apoptosis.
Recent studies with human breast cancer cell lines demonstrate that inhibition of ErbB2 receptors with trastuzumab enhances the cytotoxic eects of radiation therapy in culture and against nude mouse xenografts .
Clinical trials with anti-ErbB2 monoclonal antibodies
Clinical trials with trastuzumab as a single agent The ®rst phase II ecacy study of trastuzumab was conducted in patients with metastatic breast carcinoma overexpressing ErbB2 . The study included 46 patients who in general had extensive metastatic disease and had received prior chemotherapy. Based on prior phase I clinical trials, patients received a loading dose of 250 mg trastuzumab on day 0, and beginning on day 7, 100 mg weekly for a total of 10 doses. Over 90% of the examined population had trastuzumab trough serum levels above the targeted 10 mg/ml level. However, suboptimal serum concentrations were found in those patients with high circulating levels of tumor-shed ErbB2 extracellular domain (a minority of the patients). Antibodies against trastuzumab were not detected in any patients. Trastuzumab was remarkably well tolerated. Among 43 evaluable patients, ®ve had clinical responses (one complete remission, and four partial remissions), for an overall response rate of 11.6%. Another important observation of this trial was that 37% of patients achieved minor responses or stable disease . The median time to progression in patients with either minor response or stable disease was 5.1 months, and the unusually long durations of disease stabilization suggest that this eect may be an authentic and clinically relevant re¯ection of the biological action of the drug. This trial provided the ®rst clinical`proof of concept' that anti-growth factor receptor directed strategies are useful in the treatment of human cancer.
In a larger phase II clinical trial of trastuzumab involving 222 women with ErbB2 positive metastatic breast cancer and two prior failed chemotherapy regimens, the results showed 2% complete responses and 12% partial responses, with a median duration of response of 9.1 months (Cobleigh et al., 1999) . Cardiac Figure 5 Antitumor activity of trastuzumab in combination with paclitaxel (TAX) or doxorubicin (doxo) against well established BT-474 tumor xenografts in athymic mice. The control group was treated with the control rhuMAb IgG, 0.3 mg/kg twice weekly intraperitoneally. Trastuzumab was given intraperitoneally twice a week for 5 weeks at a dose of 0.3 mg/kg. Paclitaxel was given intravenously at a dose of 10 mg/kg days 1 and 4. Doxorubicin was administered intraperitoneally at a dose of 10 mg/kg of body weight on day 1. Doxorubicin and paclitaxel, given each in combination with the control antibody, resulted in an equipotent, but modest, antitumor activity. Trastuzumab (HER2) resulted in a modest inhibition of growth. The combined treatment with trastuzumab plus either paclitaxel or doxorubicin resulted in a marked enhancement of the antitumor eects of both chemotherapeutic agents, with greater inhibition of tumor growth in the group of animals treated with paclitaxel and trastuzumab The EGF receptor family as targets for cancer therapy J Mendelsohn and J Baselga dysfunction was observed in 10 patients, six of them symptomatic including one death from a ventricular arrhythmia; all had either prior anthracycline chemotherapy or had a cardiac history. In a more recent study analysing the activity of trastuzumab in 112 evaluable patients with ErbB2 positive metastatic breast cancer as ®rst line therapy, there were six complete remissions and 20 partial remissions, with an overall response rate of 23% and a median duration of response of 8 months (Vogel et al., 2000) . The response rate in the group of patients with the higher level of ErbB2 overexpression (3+) (n=85) was 31%.
Clinical trials with trastuzumab and chemotherapy Based on the preclinical synergism observed in xenograft studies, a phase II study of trastuzumab with cisplatin was conducted in patients with extensively pretreated advanced breast cancer with erbB2 overexpression and disease progression during standard chemotherapy . Of 37 patients assessable for response, nine (24.3%) achieved a partial response, with a median response duration of 5.3 months. There was no evidence that trastuzumab enhanced the toxicity of cisplatin. The 24% response rate observed with the combination is greater that the reported response rate with cisplatin alone in patients who have been previously treated with other chemotherapeutic agents for their metastatic disease (0 ± 7%).
The clinical responses observed with trastuzumab alone and in combination with cisplatin led to the design of a pivotal phase III clinical trial. Because of the known high antitumor activity of doxorubicin and paclitaxel in breast cancer, and the data from xenograft model studies showing enhanced activity of paclitaxel or doxorubicin in combination with trastuzumab, these two chemotherapeutic agents were selected for investigation in patients with advanced breast cancers, overexpressing ErbB2 and unexposed to prior chemotherapy Norton et al., 1999) . The patients received doxorubicin and cyclophosphamide (AC) (n=281) or paclitaxel (n=188) as their chemotherapeutic regimen if they had not received prior adjuvant doxorubicin, or paclitaxel if previously exposed to doxorubicin. Half the patients (strati®ed by the chemotherapeutic regimen received) were randomized to additionally receive trastuzumab. A syndrome of myocardial dysfunction similar to that observed with anthracyclines was reported more commonly with AC plus trastuzumab (16% Grade 3/4) than with AC alone (3%), paclitaxel alone (1%), or paclitaxel plus trastuzumab (2%). The explanation for this increased cardiac toxicity with the combination of trastuzumab plus AC is under study.
The bene®ts of adding trastuzumab to the chemotherapeutic regimens used are summarized in Table  3 . After a median follow-up of 35 months, addition of trastuzumab to chemotherapy was associated with signi®cantly improved time to disease progression (TTP) (7.4 vs 4.6 months) compared with chemotherapy alone Norton et al., 1999) . The increase was higher in the trastuzumab plus paclitaxel subgroup (6.9 vs 2.7 months) than in the trastuzumab plus AC subgroup (7.8 vs 6.1 months). Patients receiving combination therapy also had a greater overall response rate (50 vs 32%) and a longer median response duration (9.1 vs 6.1 months). Importantly, addition of trastuzumab to either form of chemotherapy also signi®cantly increased the median survival time by 25%, from 20 ± 25 months (P50.05), compared to chemotherapy alone. An enhanced survival was seen despite 65% of the chemotherapy-alone patients crossing over at disease progression to subsequently receive trastuzumab, a design that would normally bias against observing a survival advantage.
In order to further establish the role of trastuzumab in the therapy of patients with breast cancer a series of additional clinical trials are either currently underway or are in the planning process. Areas that appear to be of major interest for further development of trastuzumab include: studies of trastuzumab in combination with other chemotherapeutic agents and regimens; new schedules with taxanes (+platinum compounds); combination studies with hormonal therapy; adjuvant and neoadjuvant studies; and studies with other types of cancers expressing ErbB2.
Conclusions
There is a large body of preclinical evidence demonstrating that targeting the EGFr (ErbB1) or ErbB2 with MAbs that block receptor function, or with direct tyrosine kinase inhibitors, is a successful approach to suppressing malignant growth, in both in vitro and in vivo model systems. Furthermore, extensive studies have shown that these compounds markedly enhance the cytotoxicity of common chemotherapeutic agents and radiation therapy. The clinical trials that were built upon these laboratory studies have con®rmed the activity of anti-growth factor receptor MAbs as anticancer agents and their ability to augment the bene®ts of standard chemotherapy and radiotherapy. The relative merits of anti-receptor mAbs and direct tyrosine kinase inhibitors will be determined in the clinic. In general, the IC 50 of the direct tyrosine kinase inhibitors against intact cultured tumor cells is greater than the IC 50 of the MAbs. The oral tyrosine kinase inhibitor has advantages over an antibody, which must be given intravenously. However, the speci®city of tyrosine kinase inhibitors that act directly on the EGFr kinase is only relative, and these molecules do aect the activities of other kinases in the cell. In contrast, the antibody approach ensures complete speci®city for the EGFr kinase. Furthermore, the MAb treatment results in receptor downregulation, which could be advantageous. MAbs have less capacity to reach normal intestinal epithelium, which appears to be an advantage for MAb-mediated EGFr blockade therapy since diarrhea was a dose-limiting toxicity with the oral kinase inhibitor but was not observed with the MAb. Finally, the Mab could be working through other mechanisms, including the activation of immune responses, which would not result from use of the low molecular weight-direct inhibitors of kinase activity.
In the future, there will be great interest in combining receptor inhibitors with agents acting upon other pathways that control cell proliferation or potentiate programmed cell death. In addition, there are many other targets for therapeutic intervention among the molecules that participate in the signal transduction pathways activated by EGFr and erbB2. Today there is a veritable explosion of new agents targeting these pathways and others involved in cell proliferation, apoptosis, cell dierentiation, metastases and angiogenesis.
The success of this hypothesis-driven development of targeted anticancer drugs is best substantiated by the recent approval of the anti-ErbB2 MAb trastuzumab for treatment of patients with metastatic breast cancer whose tumors overexpress ErbB2. In the case of antiEGFr agents in combination with chemotherapy or radiotherapy, the anti-EGFr MAb IMC-C255 is in pivotal phase III clinical trials as well as phase II trials immediately following drug failure, and the oral EGFr tyrosine kinase inhibitor ZD1839 has entered phase III trials. A number of other MAbs and direct kinase inhibitors are also under investigation. These clinical studies should assist us in further de®ning the role of anti-EGF receptor agents. Hence, after nearly two decades of intensive research in the ®eld, the hypothesis that targeting growth factor receptors may become a useful strategy in the treatment of cancer has proven to be correct for two receptors in the EGF receptor family.
Abbreviations MAb, monoclonal antibody; EGFr, epidermal growth factor receptor; TGF-a, transforming growth factor alpha; HB-EGF, heparin binding EGF.
